Rigel Pharmaceuticals Inc at Citi BioPharma Conference (Virtual)- Panel: State of Play for COVID-19 Therapeutics Transcript
Okay. Great. Hopefully, everyone can hear me. This is Yigal Nochomovitz. I'm one of the biotech analysts at Citi. I'm pleased to have with me, my colleague, Joel Beatty who covers one of the companies on the panel. I cover Eiger and Rigel, and Joel covers Pliant. I am very pleased to have with me several leadership members of the panel. From Eiger, we have David Cory, President and CEO; from Pliant, we have Scott Turner, the Head of Biology; and from Rigel, we have Raul Rodriguez, who is also the President and CEO.
Welcome, everyone, to the panel. Looking forward to a good discussion. Obviously, the focus here is on the COVID-19 therapeutics that all of you have embarked on.
(Operator Instructions)
Questions & Answers
So with that, I guess, maybe just to get off for everyone, and we can kind of go around the panel. Everyone can answer. It would be interesting just to get your high-level
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |